Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.55 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | MAP2 | P11137 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | GPR3 | P46089 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.44 |
| ▸ | GABRD | O14764 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30006934 | 1.00 | IMPDH2 (0.55) | IMPDH2IMPDH1PARP1ALDH1A1ATM | |
| SCHEMBL30007584 | 0.87 | PARP1 (0.44) | IMPDH2IMPDH1PARP1ALDH1A1ATM | |
| SCHEMBL30749415 | 0.84 | PARP1 (0.73) | IMPDH2IMPDH1PARP1ALDH1A1ATM | |
| SCHEMBL30455376 | 0.84 | PARP1 (0.73) | IMPDH2IMPDH1PARP1ALDH1A1ATM | |
| SCHEMBL2183473 | 0.84 | PARP1 (0.73) | IMPDH2IMPDH1PARP1ALDH1A1ATM | |
| SCHEMBL15995219 | 0.82 | HTR7 (0.46) | PARP1ALDH1A1KDM4EGAA | |
| SCHEMBL6007642 | 0.82 | IMPDH2 (0.55) | IMPDH2IMPDH1PARP1ALDH1A1ATM | |
| SCHEMBL14924257 | 0.81 | PARP1 (0.56) | PARP1ALDH1A1ATMPIM1PIM3 | |
| SCHEMBL30849286 | 0.81 | KIF11 (0.50) | PARP1ALDH1A1GABRPGABRDGABRA1 | |
| SCHEMBL9149047 | 0.81 | PIM1 (0.50) | PARP1ALDH1A1PIM1PIM3MAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105008352-B | Carbazole compounds useful as bromodomain inhibitors | 百时美施贵宝公司 | 2018-12-07 | — | — | CN | claimed |
| CN-102584679-B | Benzocarbazole acylamide compound and preparation method and application thereof | SHANGHAI INST MATERIA MEDICA | 2015-06-17 | — | — | CN | claimed |
| CN-104098506-A | Preparation method and application of benzo[c] carbazole amide compound | UNIV EAST CHINA SCIENCE & TECH | 2014-10-15 | — | — | CN | claimed |
| CN-102584679-A | Benzocarbazole acylamide compound and preparation method and application thereof | SHANGHAI INST MATERIA MEDICA | 2012-07-18 | — | — | CN | claimed |
| CN-1450893-A | Method for treatment of sepsis | LILLY CO ELI (US) | 2003-10-22 | — | — | CN | claimed |
| CN-1240210-A | Substituted tricyclic compound | LILLY CO ELI (US) | 2000-01-05 | — | — | CN | claimed |
| US-20250228944-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12171831-B2 | Compounds and methods for the targeted degradation of bromodomain- containing proteins | ARVINAS OPERATIONS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11554171-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | ARVINAS OPERATIONS, INC. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | ARVINAS OPERATIONS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| CN-110229093-A | Carbazole compound for in-vivo imaging | 通用电气健康护理有限公司 | 2019-09-13 | — | — | CN | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0950657-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999025340-A1 | TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998018464-A1 | SUBSTITUTED TRICYCLICS | ELI LILLY AND COMPANY (US) | 1998-05-07 | — | — | WO | disclosed |
| EP-0839806-A1 | Substituted tricyclics | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772962-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | BRPF3, STUB1, BRDT | IMPDH2 3047/4885IMPDH1 3045/4885PARP1 452/4885 |
| US-11554171-B2 | Compounds and methods for the targeted degradation of bromodomain-containing proteins | BRPF3, STUB1, BRDT | IMPDH2 3047/4885IMPDH1 3045/4885PARP1 452/4885 |
| US-20210187108-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | IMPDH2 3047/4885IMPDH1 3045/4885PARP1 452/4885 |
| US-12171831-B2 | Compounds and methods for the targeted degradation of bromodomain- containing proteins | BRPF3, STUB1, BRDT | IMPDH2 3047/4885IMPDH1 3045/4885PARP1 452/4885 |
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | IMPDH2 3047/4885IMPDH1 3045/4885PARP1 452/4885 |
| US-20250228944-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | IMPDH2 3047/4885IMPDH1 3045/4885PARP1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.